Cd45 ra fitc clone hi100

Manufactured by BioLegend

CD45 RA FITC (clone HI100) is a fluorescent antibody that binds to the CD45RA isoform of the CD45 protein. CD45 is a receptor-like protein tyrosine phosphatase that is expressed on the surface of leukocytes. The CD45RA isoform is found on naive T cells and some memory B cells.

Automatically generated - may contain errors

Lab products found in correlation

Live dead fixable aqua dead cell stain kit, by Thermo Fisher Scientific (1 mentions) Ccr7 percp cy5, by BioLegend (1 mentions) Cd19 pe cy7 clone hib19, by BioLegend (1 mentions) Clone g043h7, by BioLegend (1 mentions) Cd4 bv605 clone rpa t4, by BD (1 mentions) Cd3 af700 clone okt3, by BioLegend (1 mentions) Cd8 pb clone sk1, by BioLegend (1 mentions) Cd56 apc cy7 clone hcd56, by BioLegend (1 mentions) Cytoflex lx, by Beckman Coulter (1 mentions) Lsrfortessa, by BD (1 mentions) 7 aminoactinomycin d 7 aad, by BD (1 mentions) Facsymphony a5, by BD (1 mentions)

Close spelling variants of this product

CD45-FITC

2 protocols using cd45 ra fitc clone hi100

PBMC Isolation and Immunophenotyping

Check if the same lab product or an alternative is used in the 5 most similar protocols

Peripheral blood mononuclear cells (PBMC) from healthy subjects were isolated from heparinized whole blood by density gradient centrifugation and 1x10⁶ PBMCs were stained with viable and dead cells LIVE/DEAD™ Fixable Aqua dead cell stain kit (Life Technologies) for 15 min followed by an extracellular staining. First CCR7 PerCp Cy 5.5 was stained (clone G043H7, Biolegend) for 15 min at 37 °C followed by CD3 AF700 (clone OKT3, Biolegend), CD4 BV605 (clone RPA-T4, BD Biosciences), CD8 PB (clone SK1, Biolegend), CD45 RA FITC (clone HI100, Biolegend), CD56 APC-Cy7 (clone HCD56, Biolegend), CD19 PE-Cy7 (clone HIB19, Biolegend), CD26 APC (clone BA5b, Biolegend) for 15 min at 4°C. Non-specific binding of Fc-receptors was blocked by 2% polyclonal IgG (Flebogamma). CD26 surface expression was measured with CytoFLEX LX (Beckman Coulter) and data was analyzed with FlowJo software 10.0.08. Gating strategies are shown in the Supplementary Information.

Szklarski M., Freitag H., Lorenz S., Becker S.C., Sotzny F., Bauer S., Hartwig J., Heidecke H., Wittke K., Kedor C., Hanitsch L.G., Grabowski P., Sepúlveda N, & Scheibenbogen C. (2021). Delineating the Association Between Soluble CD26 and Autoantibodies Against G-Protein Coupled Receptors, Immunological and Cardiovascular Parameters Identifies Distinct Patterns in Post-Infectious vs. Non-Infection-Triggered Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Frontiers in Immunology, 12, 644548.

+ Open protocol

+ Expand

Multiparametric Flow Cytometry of CAR T Cells

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cell-surface CAR expression was detected with two non-commercial antibodies. The allophycocyanin (APC)-labeled anti-CD19-CAR antibody has been used in prior work and binds to the Hu19 scFv.¹⁰ (link) The pacific blue-labeled anti-CD20-CAR antibody binds to the Hu20 scFv. T cells (5 × 10⁵) were suspended in 50 μL staining buffer (0.4% bovine serum albumin, 0.1% sodium azide in PBS), and antibodies were added. T cells were also stained with the following antibodies: CD3 APC-cyanine-7 clone UCHT1 (BD Biosciences); CD4 fluorescein isothiocyanate (FITC) clone RPA-T4 (BD Biosciences); CD8 R-phycoerythrin cyanine-7 (PE-Cy7/eFluor450) clone RPA-T8 (BD Biosciences or Thermo Scientific), C-C chemokine receptor 7 PE dazzle 594, clone G043H7 (Biolegend), and CD45RA FITC clone HI100 (Biolegend).
Flow cytometry was performed with a LSRFortessa (BD) or FACSymphony A5 (BD) cytometers. Dead cells were excluded with 7-amino-actinomycin D (7-aad; BD Biosciences). The gating strategy is shown in Figure S16. Flow cytometry analysis for all experiments was performed with FlowJo (Tree Star, Inc.).

Lam N., Finney R., Yang S., Choi S., Wu X., Cutmore L., Andrade J., Huang L., Amatya C., Cam M, & Kochenderfer J.N. (2023). Development of a bicistronic anti-CD19/CD20 CAR construct including abrogation of unexpected nucleic acid sequence deletions. Molecular Therapy Oncolytics, 30, 132-149.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!